CytoSorbents Corporation (CTSO)

[techxen]

Hemopure, they stated that the ticagrelor trial would be the fastest, least expensive, highest visibility of any of their applications for potential U.S. approval. Seeing that a Hemodefend pRBC trial was going to be 20 patients and 2 sites and take around 6 months to a year, I find it pretty hard to believe it could be smaller and shorter than that - but then again compared to "not requiring a trial", perhaps this could be true. I will dig around in my notes to see if there was any mention of this from previous calls and report back if I find any references.